<DOC>
	<DOCNO>NCT02079194</DOCNO>
	<brief_summary>To compare efficacy safety clopidogrel monotherapy versus aspirin plus P2Y12 antagonist follow 3-month DAPT patient undergo PCI DES .</brief_summary>
	<brief_title>Comparison Between P2Y12 Antagonist Monotherapy Dual Antiplatelet Therapy After DES</brief_title>
	<detailed_description>This trial prospective , randomize , multi-center , open label , noninferiority trial . Patients undergo PCI DES eligible . After successful PCI DES , eligible patient randomize either clopidogrel monotherapy aspirin plus P2Y12 antagonist follow 3-month DAPT .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<criteria>Subject must least 20 year age . Subject able verbally confirm understandings risk , benefit treatment alternative he/she his/her legally authorize representative provide write informed consent prior study related procedure . Patients undergo successful PCI Hemodynamic instability cardiogenic shock Active bleeding Known hypersensitivity contraindication study medication Female childbearing potential , unless recent pregnancy test negative , possibly plan become pregnant time enrollment study Noncardiac comorbid condition present life expectancy &lt; 2 year may result protocol noncompliance ( per site investigator 's medical judgment ) . Angiographic exclusion criterion Bifurcation lesion require side branch stenting Lesions treat 3 overlap stent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Drug-eluting stent</keyword>
	<keyword>aspirin</keyword>
	<keyword>P2Y12 antagonist monotherapy</keyword>
</DOC>